Kymera Investor Presentation Deck

Plasma KT-413 Concentration (ng/mL) 1000 100 10 O Plasma PK Showing Dose-Proportional Increase in Exposure 4 8 12 Cycle 1 Plasma PK 24 Time (h) KYMERA ©2023 KYMERA THERAPEUTICS, INC. 48 DL1: 0.16 mg/kg DL2: 0.32 mg/kg DL3: 0.51 mg/kg DL4: 0.82 mg/kg 72 PK Parameter Cmax (ng/mL) AUC inf (ug.h/mL) Vd (L/kg) CL (L/h/kg) t₁/2 (h) Cycle 1 PK Parameters DL2 DL1 DL3 0.16 mg/kg 0.32 mg/kg 0.51mg/kg (n = 1) (n = 1) (n = 1) 140 1380 10.1 0.116 60.3 546 3750 4.51 0.0853 36.7 598 7580 5.41 0.0673 55.8 Individual values shown for DL1-DL3; Mean (individual values) shown for DL4 since data from only 2 patients is available. DL4 0.82mg/kg (n = 2) 1500 (1140, 1850) 9340 (10800, 7860) 4.66 (3.92, 5.40) 0.0901 (0.0758, 00104) 35.9 PAGE 38

View entire presentation